NBIX: Biotech growth is driven by innovation, AI adoption, and a diversified, resilient product pipeline
China's innovation is reshaping biotech competition, prompting a focus on speed and selectivity in R&D. AI adoption is driving productivity, while Medicare policy changes will impact pricing in 2029. Growth is supported by strong commercial performance and a robust pipeline, with key data readouts…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.